We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour

By LabMedica International staff writers
Posted on 09 Aug 2023
Print article
Image: The FDA has cleared the Alinity h-series lab instruments, enabling advanced testing of patients’ CBCs (Photo courtesy of Abbott)
Image: The FDA has cleared the Alinity h-series lab instruments, enabling advanced testing of patients’ CBCs (Photo courtesy of Abbott)

Complete blood counts (CBCs) are frequently requested in healthcare for screening various disorders like infections, anemia, immune system diseases, and blood cancers. Now, the U.S. Food and Drug Administration's (FDA) clearance for an advanced hematology system paves the way for laboratories throughout the U.S. to run CBCs in the most efficient manner possible.

Abbott (Lake Forest, IL, USA) has secured U.S. FDA approval for its state-of-the-art Alinity h-series hematology system. This system can seamlessly integrate into the existing Alinity lab systems set up across the U.S., enhancing the capabilities of these laboratories. As a result, hospitals can more readily execute CBCs, which are among the top-requested tests for patients. The Alinity h-series system offers several advantages for laboratories including the ability to process up to 119 CBC results per hour which is among the fastest on the market and the requirement for less floor space, which is critical for labs to maximize resources and operations.

The Alinity h-series boasts of the Alinity hq, an automated blood analyzer, and the Alinity hs, a combined slide creator and stainer. A standout feature of the Alinity hq is its innovative MAPS™ technology that utilizes light scattering to distinguish cellular features and better recognize different blood cells. With the Alinity h-series, Abbott now offers one of the broadest laboratory diagnostic systems, offering an extensive range of tests for timely and efficient patient care. U.S. labs and hospitals will find it easy to incorporate the Alinity h-series hematology system into their primary operations with minimal effort and training for their staff. This ease of integration is crucial for labs grappling with time and resource constraints. In the U.S., the Alinity portfolio now spans the Alinity h-series (hematology), Alinity ci (clinical chemistry and immunoassay), Alinity m (molecular), Alinity s (transfusion), and the point-of-care i-STAT Alinity.

“U.S. healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic,” said Louis Morrone, executive vice president for Abbott’s core diagnostics business. “The Alinity h-series system, as with the entire suite of Alinity products, was developed to transform the way laboratories run tests so they can focus on their most important mission: the delivery of patient care.”

Related Links:
Abbott

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.